Raghuram Selvaraju

Thomas Flaten

Nazibur Rahman

James Sidoti

Naz Rahman

- Assertio Holdings, Inc.'s subsidiary, Spectrum Pharmaceuticals, Inc., entered into an **amendment and restatement of its supply agreement** with Hanmi Pharmaceutical Co. Ltd. for **ROLVEDON drug substance** on **October 7, 2025**.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]** 
- The amendment establishes **long-term pricing** for ROLVEDON, including a **mid-single digit percentage reduction** to the price Spectrum previously agreed to pay.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]** 
- The new price is **fixed throughout the remaining term** of Spectrum's license agreement, subject to potential price increases from **January 1, 2028**, if the supplier's costs exceed a set threshold, and potential reductions if global market volume for ROLVEDON exceeds a specified threshold.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]** 
- Spectrum is required to provide an **annual forecasted purchase plan**, with **at least fifty percent** of any included orders designated as binding, though there are no minimum purchase requirements.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]**

Assertio Holdings (ASRT)